Methods for crystallization of drugs
AssigneeBoston Scientific Scimed, Inc.
InventorsHongxia Zeng, Jonathan Pascal Chaky, Yen-Lane Chen
Life of this patent
Estimating the term…
Abstract
Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.
Claims16
A method for crystallizing a drug, the method comprising:
- combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension;
- wherein the nucleation initiator includes microcrystals characterized by a flat sheet morphology;
- and
- incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.
A method for crystallizing a drug, the method comprising:
- combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension;
- wherein the nucleation initiator includes everolimus microcrystals formed as relatively flat, thin sheets;
- and
- incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.
A method for crystallizing a drug, the method comprising:
- combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension;
- wherein the nucleation initiator includes everolimus microcrystals having a non-zero width less than 3 micrometers and a non-zero thickness that is less than 1 micrometer;
- and
- incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.
Dependencies are inferred from the claim text.